Applied DNA to Report Fiscal 2020 Third Quarter Financial Results After Market Close on August 6, 2020
July 30 2020 - 11:29AM
Business Wire
- Conference Call and Webcast Scheduled for
4:30 p.m. EDT-
Applied DNA Sciences, Inc. (NASDAQ: APDN) announced today that
it will report fiscal 2020 third quarter financial results after
market close on Thursday, August 6, 2020. The Company’s management
will discuss the results during a conference call and simultaneous
webcast at 4:30 p.m. EDT that same day. Presentation slides will
also be posted to the Investors section of the Company’s website
and embedded into the webcast at that time.
Conference Call
and Webcast Information - Live
Date:
Thursday, August 6, 2020, at 4:30 p.m.
Eastern Daylight Time
Dial in:
844-887-9402
412-317-6798 (international)
Conference ID: 10146786
Hosts:
Dr. James A. Hayward, chairman, president,
and CEO
Beth Jantzen, chief financial officer
Webcast:
https://services.choruscall.com/links/apdn200806.html
Conference Call
and Webcast Information - Replay
A telephonic replay of the conference call
will be available for one week beginning one hour after the end of
the live conference call.
Dial in:
877-344-7529
412-317-0088 (international)
Conference ID: 10146786
Webcast:
https://services.choruscall.com/links/apdn200806.html
Availability:
Telephonic replay: until Thursday, August
13, 2020; webcast replay: 1 year
The webcast will also be archived within
the ‘IR Calendar - Events and Presentations’ portion of the
‘Investors’ page to the company’s website.
About Applied DNA Sciences, Inc.
Applied DNA is a provider of molecular technologies that enable
supply chain security, anti-counterfeiting and anti-theft
technology, product genotyping and pre-clinical nucleic acid-based
therapeutic drug candidates.
Visit adnas.com for more information. Follow us on Twitter and
LinkedIn. Join our mailing list.
The Company’s common stock is listed on NASDAQ under ticker
symbol ‘APDN’, and its publicly-traded warrants are listed on OTC
under ticker symbol ‘APPDW’.
Applied DNA is a member of the Russell Microcap® Index.
Forward-Looking Statements
The statements made by Applied DNA in this press release may be
“forward-looking” in nature within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934 and the Private Securities Litigation Reform Act of
1995. Forward-looking statements describe Applied DNA’s future
plans, projections, strategies and expectations, and are based on
assumptions and involve a number of risks and uncertainties, many
of which are beyond the control of Applied DNA. Actual results
could differ materially from those projected due to the possibility
of a failure to make timely payment on its outstanding secured
convertible notes and resulting enforcement by noteholders of
remedies on collateral which includes substantially all of Applied
DNA’s assets, its history of net losses, limited financial
resources, limited market acceptance, the uncertainties inherent in
research and development, future clinical data and analysis,
including whether any of Applied DNA’s or its partners vaccine
candidates will advance further in the preclinical research or
clinical trial process, including receiving clearance from the U.S.
Food and Drug Administration or equivalent foreign regulatory
agencies to conduct clinical trials and whether and when, if at
all, they will receive final approval from the U.S. FDA or
equivalent foreign regulatory agencies, the unknown outcome of any
applications or requests to U.S. FDA or equivalent foreign
regulatory agencies, disruptions in the supply of raw materials and
supplies, and various other factors detailed from time to time in
Applied DNA’s SEC reports and filings, including our Annual Report
on Form 10-K filed on December 12, 2019 and our subsequent
quarterly reports on Form 10-Q filed on February 6, 2020 and May
14, 2020, and other reports we file with the SEC, which are
available at www.sec.gov. Applied DNA undertakes no obligation to
update publicly any forward-looking statements to reflect new
information, events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events, unless otherwise
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200730005739/en/
Investor contact: Sanjay M. Hurry, Applied DNA Sciences,
917.733.5573, sanjay.hurry@adnas.com Web: www.adnas.com
Twitter: @APDN
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024